Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA-Mediated Sonodynamic Therapy in Newly Diagnosed Butterfly Glioma
NCT07862647Phase 1Recruiting
- Sponsor
- Alpheus Medical
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by Alpheus Medical. Primary endpoint: Treatment-related adverse events at 30 weeks. Started Oct 2026; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07862647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862647.